The introduction of combined BRAF and MEK inhibition (e.g., dabrafenib plus trametinib; encorafenib plus binimetinib) has significantly advanced treatment for BRAF V600E-mutant NSCLC (22). The gene discussed is BRAF; the disease is non-small cell lung carcinoma.